Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017636 (
glioblastoma
)
18,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Gene fusion is one of the hallmarks of cancer. Recent advances in RNA-seq of cancer transcriptomes have facilitated the discovery of fusion transcripts. In this study, we report identification of a surprisingly large number of fusion transcripts, including six
KANSARL
(
KANSL1
-
ARL17A
) transcripts that resulted from the fusion between the
KANSL1
and
ARL17A
genes using a RNA splicingcode model. Five of these six
KANSARL
fusion transcripts are novel. By systematic analysis of RNA-seq data of
glioblastoma
, prostate cancer, lung cancer, breast cancer, and lymphoma from different regions of the World, we have found that
KANSARL
fusion transcripts were rarely detected in the tumors of individuals from Asia or Africa. In contrast, they exist in 30 - 52% of the tumors from North Americans cancer patients. Analysis of CEPH/Utah Pedigree 1463 has revealed that
KANSARL
is a familially-inherited fusion gene. Further analysis of RNA-seq datasets of the 1000 Genome Project has indicated that
KANSARL
fusion gene is specific to 28.9% of the population of European ancestry origin. In summary, we demonstrated that
KANSARL
is the first cancer predisposition fusion gene associated with genetic backgrounds of European ancestry origin.
...
PMID:Identification of
KANSARL
as the first cancer predisposition fusion gene specific to the population of European ancestry origin. 2888 86